PI-103

Catalog No.S1038

PI-103 Chemical Structure

Molecular Weight(MW): 348.36

PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

5 Customer Reviews

  • (D) IGROV parental, shControl (two independent clones) and ShPKCiota (two independent clones) were treated with 5 μM GDC-0941 and 1.5 μM PI-103 for 24 hours and subjected to western blot analysis with the indicated antibodies. Each experiment was performed in triplicate.

    Oncogene, 2016, 35(19):2428-40. PI-103 purchased from Selleck.

    (A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.

    Mol Carcinog 2012 52, 667-75 . PI-103 purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. PI-103 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine PI-103 purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of PI-103 for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.
Features The first potent, synthetic mTOR inhibitor.
Targets
p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)
DNA-PK [3]
(Cell-free assay)
2 nM 3 nM 3 nM 15 nM 23 nM
In vitro

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-BE MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S1eFAuQCEQvF2= NEPJe3gzPC92OD:3NkBp NF;6WFhqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To MlztNlYzOjR4OEG=
SH-SY5Y Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrvSHYxNThizszN NV\SNlMyOjRxNEivO|IhcA>? MYfpcoR2[2W|IITpcYUuKGGwZDDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1cW:wIH;uJG5DKGOnbHyg[5Jwf3Sq MlLRNlYzOjR4OEG=
SH-SY5Y  NGqwfG1CeG:ydH;zbZMhSXO|YYm= NV23VmI6OSEQvF2= MlHONE42NTJ2IHi= NGfFXoF{\W6|aYTpfoV{KG6ndYLvZoxie3SxbXGgZ4VtdHNidH:g[I95d3K3YnnjbY4ucW6mdXPl[EBieG:ydH;zbZM> M1\OTVI3OjJ2Nkix
G 35 SC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPuUXl6OC5yNT2yNEDPxE1? M2DKOFI1Nzd{IHi= NUXsPFhuTE2VTx?= NVzHVXY1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= M4O3U|I3OTJzMkWx
G 38 SC NYLrS|ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW2NGMxNjB3LUKwJO69VQ>? MoPFNlQwPzJiaB?= NUfWTGc2TE2VTx?= M1jVWolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NV;w[ow5OjZzMkGyOVE>
G 40 SC M{nYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHLWmU2OC5yNT2yNEDPxE1? MoPaNlQwPzJiaB?= Ml\WSG1UVw>? NETPU2NqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 MUWyOlEzOTJ3MR?=
G 35 DC NXfve2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmwMlA2NTJyIN88US=> M1HrV|I1Nzd{IHi= Ml7WSG1UVw>? NWH3bJR3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NXHuR4I2OjZzMkGyOVE>
G 38 DC NFLYOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVywMlA2NTJyIN88US=> NYW3UZZTOjRxN{KgbC=> NE\ySYdFVVOR M1[y[YlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MX2yOlEzOTJ3MR?=
G 40 DC MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\5clAvODVvMkCg{txO M3fEe|I1Nzd{IHi= NF;CZXhFVVOR M4HjTYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M{m0[|I3OTJzMkWx
RD NV7ZOFZuSXCxcITvd4l{KEG|c3H5 NGnMUJoyNzFwNT:yJO69VQ>? M{P0cVczKGh? NUfRV29qcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? M1Xy[FI2PzR7M{e4
TE381.T MkfvRZBweHSxc3nzJGF{e2G7 MX6xM|EvPS9{IN88US=> MW[3NkBp NID6ZpFqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? Mmf2NlU4PDl|N{i=
RMS13 NWnBXlJqSXCxcITvd4l{KEG|c3H5 NFTNeIkyNzFwNT:yJO69VQ>? Mn\JO|IhcA>? M{T2NYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy NFixZY8zPTd2OUO3PC=>
RH30  Mke4RZBweHSxc3nzJGF{e2G7 MY[xM|EvPS9{IN88US=> NHiwNHo4OiCq NGfuZZNqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? MYiyOVc1QTN5OB?=
VJ MoXqRZBweHSxc3nzJGF{e2G7 NFrSW|QyNzFwNT:yJO69VQ>? Mn\aO|IhcA>? MUTpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MmPLNlU4PDl|N{i=
HS578T NELjTmVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXLxbItlOC1|IN88US=> Mo\ZO|IhcA>? NYL2SIdNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MYmyOVczOTRzOR?=
BT549 NHTGVHlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHzPfW4xNTNizszN MnP0O|IhcA>? MUTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M3fDU|I2PzJzNEG5
MDA-MB-231 MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWXtRpVQOC1|IN88US=> MnfQO|IhcA>? Mn\xbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MUSyOVczOTRzOR?=
MDA-MB-468 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXjxdotzOC1|IN88US=> NFX2U2s4OiCq MWfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{P3eFI2PzJzNEG5
MDA-MB-436 NYPzTolCS2WubDDWbYFjcWyrdImgRZN{[Xl? NXvBO3VvOC1|IN88US=> NH;WTpo4OiCq NGCwe4NqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MmrRNlU4OjF2MUm=
SUM149PT NVf3UJlQS2WubDDWbYFjcWyrdImgRZN{[Xl? NGfjTGoxNTNizszN NHrRZZA4OiCq MVvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M2X0cVI2PzJzNEG5
MDA-MB-468 M3fyUmZ2dmO2aX;uJGF{e2G7 MVqwMlAyNTFyIN88US=> M1n2UFI1KGh? NGXmNY1ld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NGfIXpczPTd{MUSxPS=>
MDA-MB-231 NE[2O|VHfW6ldHnvckBCe3OjeR?= MXqwMlAyNTFyIN88US=> NX3C[W41OjRiaB?= M3HveYRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NE\LN2kzPTd{MUSxPS=>
HS578T NIPMeXdHfW6ldHnvckBCe3OjeR?= NE\RVVkxNjBzLUGwJO69VQ>? MonONlQhcA>? NX7KeIV2\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXzzJI9nKM7{LWTyR3AyNCClLV35Z{BidmRiY4njcIlvKEVicILveIVqdnQEoB?= MUiyOVczOTRzOR?=
SW872 MX;GeY5kfGmxbjDBd5NigQ>? MmfhNE4xOS1yLkWg{txO M{HMSVI1KGh? NH;5Z2Nz\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> M{LHZlI1Pjl3NkOy
SW982 NVPTNWdRTnWwY4Tpc44hSXO|YYm= NW\pb|dtOC5yMT2wMlUh|ryP MUSyOEBp NXHadoNoemWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MonlNlQ3QTV4M{K=
SW872 NUTFUFB2SXCxcITvd4l{KEG|c3H5 MYGwMlAyNTBwNTFOwG0> NYTlcoxYPDhiaB?= NX;GfII3cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MkHsNlQ3QTV4M{K=
SW982 MnnYRZBweHSxc3nzJGF{e2G7 NELKV3YxNjBzLUCuOUDPxE1? NGjidXE1QCCq MYfpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NYm0TZNoOjR4OUW2N|I>
AGS HG Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zHWmlEPTB;MD62PEDDuSByLkCzNUDPxE1? NUP3WVBZOjR3OUe0O|g>
AGS LG NGm3dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEWgxtEhOC5yMEGg{txO NV7IdnV6OjR3OUe0O|g>
HGC27 HG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xV|BKSzVyPUCuN|ghyrFiMD6wNlIh|ryP NF;2NoIzPDV7N{S3PC=>
HGC27 LG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjlTWM2OD1yLkCyJOKyKDBwMEC0JO69VQ>? NHHw[YMzPDV7N{S3PC=>
MKN45 HG MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLiRnA2UUN3ME2xMlAyKMLzIECuNFUyKM7:TR?= NEnSUmUzPDV7N{S3PC=>
MKN45 LG M4jPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rpXWlEPTB;MD64O{DDuSByLkCzNEDPxE1? MX6yOFU6PzR5OB?=
NUGC4 HG MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjm[4d3UUN3ME2xOE4xKMLzIEOuPVE{KM7:TR?= MmTYNlQ2QTd2N{i=
NUGC4 LG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjOTWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? MXKyOFU6PzR5OB?=
A549 MlLrSpVv[3Srb36gRZN{[Xl? MnnnNE4zPS9yLkWvNUDPxE1? MVuyOEBp M2HoZ4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2yrZ3j0cJk> MnHpNlQ{PTF2MkW=
H460 MV7GeY5kfGmxbjDBd5NigQ>? NGXI[IsxNjJ3L{CuOU8yKM7:TR?= NF3LSpozPCCq NX7YdJF2cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? M3HEfFI1OzVzNEK1
H661 MW\GeY5kfGmxbjDBd5NigQ>? M3vaU|AvOjVxMD61M|Eh|ryP NV3CRWRJOjRiaB?= M{nBdIlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= MkTCNlQ{PTF2MkW=
SAS NFu5d3VHfW6ldHnvckBCe3OjeR?= M{\0TlAvOjVxMD61M|Eh|ryP M4\5c|I1KGh? NFrXNIxqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= NET2N|AzPDN3MUSyOS=>
UT5 NI\lZpFHfW6ldHnvckBCe3OjeR?= M2D5RlAvOjVxMD61M|Eh|ryP NWrQN2JmOjRiaB?= M{PVSYlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= MXuyOFM2OTR{NR?=
FaDu Mn31SpVv[3Srb36gRZN{[Xl? MmjVNE4zPS9yLkWvNUDPxE1? MlH3NlQhcA>? M4\ZdIlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= MViyOFM2OTR{NR?=
RD MlfCRZBweHSxc3nzJGF{e2G7 NHf6ZmIyNzFwNT:yJO69VQ>? MkP0O|IhcA>? MoTqSG1UVw>? NVrNOmdOcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? NH\Oe|EzOzZ6NEmyOS=>
TE671 MnzXRZBweHSxc3nzJGF{e2G7 MmLFNU8yNjVxMjFOwG0> NILPe2w4OiCq NVXhVmd6TE2VTx?= MoqwbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> NU\ocVlROjN4OES5NlU>
RH30  M4f1XGFxd3C2b4Ppd{BCe3OjeR?= MmDxNU8yNjVxMjFOwG0> M4jweFczKGh? MortSG1UVw>? MmfvbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> NUfGR|N5OjN4OES5NlU>
RMS13 NVSwWIV4SXCxcITvd4l{KEG|c3H5 M{PtOVEwOS53L{Kg{txO NEi0WoQ4OiCq MX\EUXNQ MUHpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 NV;uOlJ7OjN4OES5NlU>
SUM149PT Mli2R4VtdCCYaXHibYxqfHliQYPzZZk> NELLVoYxNjNizszN MVm3NkBp M1X1bIVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? MXyyN|YxOTB5NB?=
MDA-MB-468 MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmTvNE4{KM7:TR?= NGLIZm04OiCq M2\qfYVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? NFfxV5czOzZyMUC3OC=>
MDA-MB-231 NXvTTmFKS2WubDDWbYFjcWyrdImgRZN{[Xl? MlX5NE4{KM7:TR?= NUiwflF5PzJiaB?= NXfP[JU2\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| NF;we4kzOzZyMUC3OC=>
SY5Y MVjGeY5kfGmxbjDBd5NigQ>? M165[lEvPS9{LkWvOUDPxE1? NWLzNlZ7OjRiaB?= MV3pcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| NULFOFFEOjN|N{izOFE>
SKNBE(2c) NUXFbHNkTnWwY4Tpc44hSXO|YYm= MlH3NU42NzJwNT:1JO69VQ>? MWeyOEBp M2nvTYlv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= MnWyNlM{Pzh|NEG=
RD NGTOVGZCeG:ydH;zbZMhSXO|YYm= M2nrcVMhyrWP NIP5VpoyOiCq NYT3O5VmTE2VTx?= NID5clh{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MVyyN|MxODhyOR?=
TP5014 MXHBdI9xfG:|aYOgRZN{[Xl? M2HlXFMhyrWP M3nTVVEzKGh? NF[3NZRFVVOR NVTKTGlJe2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> NWfaW5hiOjN|MEC4NFk>
HT1080 MmfLRZBweHSxc3nzJGF{e2G7 NVjQ[49kOyEEtV2= NWLHZnp6OTJiaB?= MlvSSG1UVw>? MlXOd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO= NEjwR3QzOzNyMEiwPS=>
A549 MXjGeY5kfGmxbjDBd5NigQ>? MUWwMVMvOyEQvF2= MnPFO|IhcA>? NWTsOY9FcW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW NIPQSnAzOzJ3OUW5NS=>
HCC827 MmjmSpVv[3Srb36gRZN{[Xl? NGewNW8xNTNwMzFOwG0> NGezWnQ4OiCq MYnpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> M{PufVI{OjV7NUmx
H3122 NXG1PG9LTnWwY4Tpc44hSXO|YYm= NU\xTZZNOC1|LkOg{txO MlPRO|IhcA>? MV7pcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> NVfGT2FrOjN{NUm1PVE>
TALL-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O5UFHjiIoQvF2= Mn;yO{Bl NIraWHZl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NU\TSJQxOjNyM{iyO|M>
HPB-ALL NVzObHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHiV4Iy6oDLzszN NHLheIQ4KGR? M1ThboRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NWHxRXFHOjNyM{iyO|M>
DND41 NFTEbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmx5qCK|ryP MlfIO{Bl MWjk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> Mlm4NlMxOzh{N{O=
SUP-T1 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6x5qCK|ryP NHjYWXQ4KGR? MlPK[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NFnoVGszOzB|OEK3Ny=>
PEER NV3oXnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17IPFHjiIoQvF2= NWHuOINzPyCm NI\s[JBl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MX6yN|A{QDJ5Mx?=
ALL-SIL NInZTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHoVY1vOeLCid88US=> Mn3RO{Bl MonG[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NHrzXZgzOzB|OEK3Ny=>
KE37 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmx5qCK|ryP M3\He|ch\A>? Mo\v[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NX;4RoV2OjNyM{iyO|M>
Karpas-45 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m4d|HjiIoQvF2= NVHQZ3R6PyCm NWTrPHp3\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MXGyN|A{QDJ5Mx?=
RPMI-8402 M1jZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z1R|HjiIoQvF2= MVS3JIQ> MWLk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NV;JWHU4OjNyM{iyO|M>
Jurkat M4DneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVex5qCK|ryP MVK3JIQ> NITDXpBl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MXOyN|A{QDJ5Mx?=
MOLT-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWx5qCK|ryP M2L1bFch\A>? NWPERYdR\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NYqwT|RlOjNyM{iyO|M>
PF-382 NWrj[mRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PrcVHjiIoQvF2= M{TLXFch\A>? NYj6c|JH\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MVeyN|A{QDJ5Mx?=
CCRF-CEM M{f3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDGNgKBkc7:TR?= Ml7kO{Bl NIq5VlBl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NUjidYhtOjNyM{iyO|M>
LOUCY NEfaeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X5TVHjiIoQvF2= M4fTOVch\A>? M3jZZoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MmPWNlMxOzh{N{O=
MOLT-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n2OVHjiIoQvF2= NGH4V5U4KGR? MUnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MYeyN|A{QDJ5Mx?=
MM1S Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLDNE0zKM7:TR?= NG\HRpczPCCq NGHUVo9KSzVyPUCuOUDPxE1? MoTMNlI5Ojl{M{S=
NCI-H929 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOwMVIh|ryP M3rRd|I1KGh? M1TI[WlEPTB;MD6yOUDPxE1? NHHqUJMzOjh{OUKzOC=>
KMS12-BM  M4XvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjZfmoxNTJizszN MXGyOEBp M3jYVmlEPTExvK6yJO69VQ>? NHjpc2IzOjh{OUKzOC=>
MDA-MB-436 NYL6OVFlTnWwY4Tpc44hSXO|YYm= NIn2dowyKM7:TR?= NYC5UXF[OjRiaB?= MUHy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NFjvVZMzOjR6OEW5NC=>
SUM149PT M3r6T2Z2dmO2aX;uJGF{e2G7 MXSxJO69VQ>? M{jyVVI1KGh? M4T0[ZJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= NXrLSlhWOjJ2OEi1PVA>
SUM1315MO2 NUDzbYhzTnWwY4Tpc44hSXO|YYm= Mmn2NUDPxE1? NXPrZXp3OjRiaB?= M2DybZJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= MoTlNlI1QDh3OUC=
HCC1937 MXPGeY5kfGmxbjDBd5NigQ>? MnHrNUDPxE1? MWKyOEBp NIn3NFJz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NILqeokzOjR6OEW5NC=>
HCC827 NEfUfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvobXgxNTNizszN Mor5O|IhcA>? MkjGTWM2OD1yLkOg{txO MXyyNVIzODR5NB?=
PC-9  NXXVXpE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jNVVAuOyEQvF2= NFfWdHo4OiCq MVzJR|UxRTBwODFOwG0> NHnTdGozOTJ{MES3OC=>
LN229 MWfGeY5kfGmxbjDBd5NigQ>? M2PIb|Eh|ryP NETzSlc1QCCq NGPh[JZqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NHzDW2szOTB4Mkm5Ny=>
U87 NX;nTVB4TnWwY4Tpc44hSXO|YYm= NULHdXE4OSEQvF2= MX20PEBp M4q3RYlv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NVO1SIl4OjFyNkK5PVM>
U373 NIC5cFFHfW6ldHnvckBCe3OjeR?= NGL4R5IyKM7:TR?= NYnC[4NUPDhiaB?= NYLTSWR2cW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NY[3cm83OjFyNkK5PVM>
SF767 MXzGeY5kfGmxbjDBd5NigQ>? NVTxe|d1OSEQvF2= NE\jTIQ1QCCq MoTVbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? M{naTVIyODZ{OUmz
Mel-Juso Mn7TR4VtdCCYaXHibYxqfHliQYPzZZk> M{O3VFAvODIkgKOxNQKBkc7:TR?= NFWxeos4OiCq MljUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MUmyNVA1QDd6NR?=
518A2  NF;SdmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml;GNE4xOeLCk{Gw5qCK|ryP M1ewbFczKGh? NYXUNIZIcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGPMT2czOTB2OEe4OS=>
Mel-Juso  MkPSSpVv[3Srb36gRZN{[Xl? NVvIcFJMOC5yMEJihLMy6oDLzszN M{TNU|I1KGh? Moe4d5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= M3HLN|IyODR6N{i1
518A2 MUXGeY5kfGmxbjDBd5NigQ>? NYX1cpRmOC5yMEJihLMy6oDLzszN MWeyOEBp NHvkc3R{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz NYH2[nprOjFyNEi3PFU>
PC3  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXzNlRp MonPS2k2OMLiPTCxNFAhdk1? NHq4SJIzODV3MUC2NS=>
U87MG NWnIW|NRTnWwY4Tpc44hSXO|YYm= M1zFSVAvOS1zIN88US=> NXXXUIw2OjUkgJnoxsA> MWfEUXNQ M4WzZYlvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p NGjQRlEyQTZ|M{[4Ny=>
U138MG M1TrbGZ2dmO2aX;uJGF{e2G7 MofjNE4yNTFizszN NX3yWnJOOjUkgJnoxsA> Ml7mSG1UVw>? MoHwbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? M3X2TVE6PjN|Nkiz
U118MG MojHSpVv[3Srb36gRZN{[Xl? NXTs[mFLOC5zLUGg{txO NGDIZoUzPOLCiXlCpC=> MnXMSG1UVw>? NVKxSHNwcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= MY[xPVY{OzZ6Mx?=
U87MG M4Tod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMUSg{txO M3HrR|E6PTh2MkK3
IGROV-1 M4LrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\YPWlEPTB;MD6wOkDPxE1? M1HwSFE6PTh2MkK3
DETROIT562 M13ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHridJlKSzVyPUCuNVMh|ryP MYKxPVU5PDJ{Nx?=
PC3  M2H2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUCg{txO M1fhVFE6PTh2MkK3
SKOV-3 NX;TfGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfofIVFUUN3ME2wMlEzKM7:TR?= NIXWTWIyQTV6NEKyOy=>
HUVEC M3\N[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vocGlEPTB;MD6wPEDPxE1? M{TW[VE6PTh2MkK3
UCH-1  MkDxSpVv[3Srb36gRZN{[Xl? MkfGNE02KM7:TR?= M1TS[IlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBCU1RiYX7kJI1VV1JiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHK4T5IyQTV{OES0NS=>
UCH-1  NXzOXnNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLHTnRzOC5yMT2xNEDPxE1? MnzOOkBl MojFbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NYjnNFdvOTl3Mki0OFE>
UCH-1  NH63e|BCeG:ydH;zbZMhSXO|YYm= NVrpRmZYOC5zLUGwJO69VQ>? MVeyOEBp MV;EUXNQ NYPZ[JhXcW6mdXPld{BieG:ydH;zbZM> NGXBWZkyQTV{OES0NS=>

... Click to View More Cell Line Experimental Data

In vivo When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]

Protocol

Kinase Assay:[3]
+ Expand

Enzyme Assays:

Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
Cell Research:[2]
+ Expand
  • Cell lines: U87MG cells
  • Concentrations: 0.5 μM
  • Incubation Time: 24 hours
  • Method: U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
  • Formulation: 50% DMSO
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 348.36
Formula

C19H16N4O3

CAS No. 371935-74-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy PI-103 | PI-103 supplier | purchase PI-103 | PI-103 cost | PI-103 manufacturer | order PI-103 | PI-103 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID